Wentworth Kerry 4

What Happened
Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio (NUVB), exercised 36,750 stock options and immediately sold the resulting 36,750 shares on April 17, 2026. The exercise recorded a $2.93 per-share cost (total cash paid $107,678) and the subsequent open-market sale reported a weighted-average price of $5.01 per share for total gross proceeds of $184,279. The filing also includes a related $0.00 derivative conversion entry associated with the option-to-share conversion.

Key Details

• Transaction date: April 17, 2026. Filing date: April 21, 2026 (filed on the Form 4 due date).
• Exercise (code M): 36,750 shares exercised at $2.93/share — cash paid $107,678.
• Sale (code S): 36,750 shares sold at a weighted-average price of $5.01/share — gross proceeds $184,279; trade prices ranged $5.00–$5.05 (footnote F2).
• Shares owned after the transaction: not reported in the provided data.
• Footnotes: Sales were made pursuant to a 10b5-1 plan dated Dec 4, 2025 (F1). The option vesting schedule is noted (25% after 1 year from Aug 29, 2022, then monthly over 36 months) (F3).
• The filing shows a $0.00 derivative conversion line tied to the exercise (reporting/administrative entry).

Context

• This was an exercise followed by an immediate sale (commonly called a cashless exercise or sell-to-cover pattern): the insider converted options into shares and sold those shares the same day. Such transactions are often routine and can be executed under trading plans (here, a 10b5-1 plan).
• Factual summary only — this report shows a disposition of shares after exercising options and does not, by itself, indicate the insider’s view on the company’s prospects.